Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Self-care in Europe

This article was originally published in The Tan Sheet

Executive Summary

Self-managing health care is becoming increasingly acceptable in Europe, Hubertus Cranz, PhD, director general of the Association of the European Self-Medication Industry (AESGP) said during CHPA's Regulatory & Scientific Conference in Washington, D.C. May 2. "Ten, 15 years ago it would have been impossible to even talk about a patient self-managing health care," he explained, describing the European setting as "much more restrictive" than that in the U.S. or UK. Progress has since been made, Cranz said, pointing out that from 2001 to 2002 the Standing Committee of European Doctors participated in AESGP's study on new indications for self-medication. In 2006, the AESGP was involved in a joint project with the World Medical Association entitled, "From Patient to Self-Health Manager." Cranz credited the UK for setting the example, explaining that the "UK government policy is to encourage self-care"...

You may also be interested in...



Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel